Analgesic Efficacy of Serratus Anterior Plane Block in The Rib Fractures Pain

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04293354

Enrollment

Registered

2020-03-03

Start date

2017-08-01

Completion date

2019-04-01

Last updated

2020-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serratus Plane Block

Brief summary

Serratus Anterior Plane Block (SAPB) is a facial plane block that was first described by Blanco in 2013 and that blocks the lateral cutaneous branches of the T2-T9 intercostal nerves, the intercostobrachial nerve, n. thoracic longus, n. thoracodorsalis nerves. Case and case series have been reported in the literature on the use of SAPB in rib fractures, and it has been reported as an effective analgesia method. We apply SAPB to patients with rib fractures with pain in our clinic. Our aim is to evaluate SAPB for patients with rib fractures pain and to compare them with the control group in terms of total analgesic consumption and pain scores.

Detailed description

After Ethics Committee approval patients with rib fracture pain and have a Numerical Rating Scale (NRS) score of ≥ 4, included the study. The patients were randomized by the closed envelope method. The patients were divided into two groups as the SAPB-performed group (Group S) and the Control group (Group K). Intravenous patient-controlled analgesia (PCA) device prepared with tramadol was applied to all patients.

Interventions

PROCEDURESerratus Plane Block

Serratus Plane Block was performed

PROCEDUREControl

No block was performed

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

Rib fracture pain and had a Numerical Rating Scale (NRS) score of ≥ 4 ASA I-II-III

Exclusion criteria

Patients with infection at the injection site Coagulopathy Allergy to amide-type local anesthetics History of peripheral neuropathy Hepatic and/or renal failure Refusing the procedure

Design outcomes

Primary

Measure	Time frame	Description
Analgesic consumption	up to 24 hour	Tramadol

Secondary

Measure	Time frame	Description
Numerical Rating Scale (NRS)	at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours	pain scores

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026